1. |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin, 2020, 70(1): 7-30.
|
2. |
Aier I, Semwal R, Sharma A, et al. A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer. Cancer Epidemiol, 2019, 58: 104-110.
|
3. |
Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res, 2014, 74(11): 2913-2921.
|
4. |
Canto MI, Almario JA, Schulick RD, et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology, 2018, 155(3): 740-751.
|
5. |
Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet, 2016, 388(10039): 73-85.
|
6. |
Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg, 2015, 261(1): 12-17.
|
7. |
Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol, 2017, 35(5): 515-522.
|
8. |
Wagner M, Antunes C, Pietrasz D, et al. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol, 2017, 27(7): 3104-3116.
|
9. |
Kluger MD, Rashid MF, Rosario VL, et al. Resection of locally advanced pancreatic cancer without regression of arterial encasement after modern-era neoadjuvant therapy. J Gastrointest Surg, 2018, 22(2): 235-241.
|
10. |
Cassinotto C, Sa-Cunha A, Trillaud H. Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer. Diagn Interv Imaging, 2016, 97(12): 1225-1232.
|
11. |
Boone BA, Steve J, Zenati MS, et al. Serum CA19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol, 2014, 21(13): 4351-4358.
|
12. |
Rieser CJ, Zenati M, Hamad A, et al. CA19-9 on postoperative surveillance in pancreatic ductal adenocarcinoma: predicting recurrence and changing prognosis over time. Ann Surg Oncol, 2018, 25(12): 3483-3491.
|
13. |
Haab BB, Huang Y, Balasenthil S, et al. Definitive characterization of CA19-9 in resectable pancreatic cancer using a reference set of serum and plasma specimens. PLoS One, 2015, 10(10): e0139049.
|
14. |
Hausmann S, Kong B, Michalski C, et al. The role of inflammation in pancreatic cancer. Adv Exp Med Biol, 2014, 816: 129-151.
|
15. |
Aziz MH, Sideras K, Aziz NA, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study. Ann Surg, 2019, 270(1): 139-146.
|
16. |
Jomrich G, Gruber ES, Winkler D, et al. Systemic immune-inflammation index (SII) predicts poor survival in pancreatic cancer patients undergoing resection. J Gastrointest Surg, 2020, 24(3): 610-618.
|
17. |
Masui T, Doi R, Kawaguchi Y, et al. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors. Surg Today, 2016, 46(11): 1282-1289.
|
18. |
Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin, 2017, 67(2): 93-99.
|
19. |
Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg, 2009, 250(2): 187-196.
|
20. |
Thanikachalam K, Damarla V, Seixas T, et al. Neoadjuvant phase Ⅱ trial of chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer. Am J Clin Oncol, 2020, 43(6): 435-441.
|
21. |
Zhan HX, Xu JW, Wu D, et al. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Cancer Med, 2017, 6(6): 1201-1219.
|
22. |
Tempero MA, Malafa MP, Chiorean EG, et al. Pancreatic adenocarcinoma, version 1.2019. J Natl Compr Canc Netw, 2019, 17(3): 202-210.
|
23. |
Epelboym I, Zenati MS, Hamad A, et al. Analysis of perioperative chemotherapy in resected pancreatic cancer: identifying the number and sequence of chemotherapy cycles needed to optimize survival. Ann Surg Oncol, 2017, 24(9): 2744-2751.
|
24. |
Kirkegård J, Mortensen FV, Cronin-Fenton D. Chronic pancreatitis and pancreatic cancer risk: a systematic review and meta-analysis. Am J Gastroenterol, 2017, 112(9): 1366-1372.
|
25. |
Zhong JH, Huang DH, Chen ZY. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget, 2017, 8(43): 75381-75388.
|
26. |
Zhang K, Hua YQ, Wang D, et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. J Transl Med, 2019, 17(1): 30.
|
27. |
Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer, 2016, 16(7): 431-446.
|
28. |
Padoan A, Plebani M, Basso D. Inflammation and pancreatic cancer: focus on metabolism, cytokines, and immunity. Int J Mol Sci, 2019, 20(3): E676.
|
29. |
Boone BA, Zenati MS, Rieser C, et al. Risk of venous thromboembolism for patients with pancreatic ductal adenocarcinoma undergoing preoperative chemotherapy followed by surgical resection. Ann Surg Oncol, 2019, 26(5): 1503-1511.
|
30. |
Meikle CK, Kelly CA, Garg P, et al. Cancer and thrombosis: the platelet perspective. Front Cell Dev Biol, 2017, 4: 147.
|